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Abstract
Background: Central diabetes insipidus (CDI) results from a number of conditions affecting the hypothalamic-
neurohypophyseal system to cause vasopressin deficiency. Diagnosis of CDI is challenging, and clinical data and
guidelines for management are lacking. We aim to characterize clinical and radiological characteristics of a cohort
of pediatric patients with CDI.
Methods: A chart review of 35 patients with CDI followed at North Carolina Children’s Hospital from 2000 to 2015
was undertaken. The frequencies of specific etiologies of CDI and characteristic magnetic resonance imaging (MRI)
findings were determined. The presence of additional hormone deficiencies at diagnosis and later in the disease
course was ascertained. Patient characteristics and management strategies were evaluated.
Results: The cohort included 14 female and 21 male patients with a median age of 4.7 years (range, less than
1 month to 16 years) at diagnosis. Median duration of follow-up was 5 years (range, 2 months to 16 years). The
cause of CDI was intracranial mass in 13 patients (37.2 %), septo-optic dysplasia in 9 patients (25.7 %), holoprosencephaly
in 5 patients (14.2 %), Langerhans cell histiocytosis in 3 patients (8.6 %), isolated pituitary hypoplasia in 2 patients (5.7 %),
and encephalocele in 1 patient (2.9 %). Patients were symptomatic for a mean of 6.3 months (range, less than 1 month to
36 months) prior to diagnosis of CDI. Growth hormone (GH), thyrotropin (TSH), adrenocorticotropic hormone (ACTH), and
gonadotropin deficiencies were present at diagnosis in 34, 23, 23, and 6 % of patients, respectively. GH, TSH, ACTH, and
gonadotropin deficiencies were diagnosed during follow-up in 23, 40, 37, and 14 % of patients, respectively. In patients
with structural CNS abnormalities, development of additional hormone deficiencies occurred anywhere from 2 months to
13 years after the time of initial presentation.
Conclusions: All patients in our cohort had an underlying organic etiology for CDI, with intracranial masses and CNS
malformations being most common. Therefore, MRI of the brain is indicated in all pediatric patients with CDI. Other
pituitary hormone deficiencies should be investigated at diagnosis as well as during follow-up.
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Background
Central diabetes insipidus (CDI) is characterized by poly-
uria, polydipsia, and the inability to concentrate urine as a
result of arginine vasopressin deficiency. Maintenance of
normal tonicity of extracellular fluids is vital to cellular
function and is regulated by the complex interaction of
fluid intake, vasopressin secretion, and urine output. Dys-
function of the system that maintains water homeostasis
may result in life-threatening hypernatremia, seizures,
dehydration, and failure to thrive. Vasopressin is synthe-
sized by neurons of the hypothalamic paraventricular and
supraoptic nuclei and secreted by the posterior pituitary
gland [1]. Therefore, malformation or damage to midline
cerebral and cranial structures may result in the absence
of vasopressin production or secretion. Known etiologies
of CDI include central nervous system (CNS) tumors,
post-neurosurgical or accidental trauma, autoimmune dis-
ease, or infiltrative diseases. Genetic mutations resulting
in abnormal synthesis of vasopressin precursor hormones
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may occur rarely [2]. In a large Danish study in 2014, the
annual incidence of CDI overall was 3 to 4 patients per
100,000 with an incidence of 2 cases of congenital CDI
per 100,000 infants [3].
CDI presents a number of diagnostic and therapeutic
challenges. The diagnosis may be delayed during evalu-
ation for more common etiologies of polydipsia and
polyuria, and often requires formal water deprivation
testing [1]. After the diagnosis of CDI is confirmed,
further work-up to determine the etiology of CDI and to
assess for additional pituitary hormone deficiencies is
necessary; however, clear guidelines for which laboratory
and imaging studies to obtain and at what intervals to
repeat these investigations are lacking.
The mainstay of therapy for CDI is desmopressin
(DDAVP), a synthetic analog of arginine vasopressin with
an extended duration of action; however, education of
patients and caregivers regarding the safe use of DDAVP is
essential to minimize risks of water-intoxication and hypo-
natremia. Risks of DDAVP-associated hyponatremia are in-
creased in neonates, in patients without an intact thirst
mechanism, and in patients requiring high-volume intra-
venous fluid hydration for chemotherapy. Given the num-
ber of diagnostic and therapeutic challenges associated with
CDI, we performed a retrospective chart review of a cohort
of pediatric patients with CDI followed at the North
Carolina Children’s Hospital (NCCH) in order to describe
our experience and to contribute further to generalizable
knowledge about the diagnosis and management of CDI.
Methods
The study was approved by the University of North
Carolina Institutional Review Board, and conducted in
compliance with the Helsinki Declaration. The NCCH
electronic medical record was reviewed in order to
identify all patients with CDI followed in pediatric
endocrinology clinic. All patients that have been eval-
uated for management or diagnosis of CDI in the
past year were included. Extracted data included pa-
tient characteristics (age, gender, race), duration of
clinical symptoms prior to diagnosis in those present-
ing with CDI, pituitary hormone laboratory evalu-
ation, family history, neuroimaging study results, and
pathology findings. Management strategies were also
reviewed.
The frequencies of various etiologies of CDI as well as
characteristic magnetic resonance imaging (MRI) find-
ings were determined. CDI was diagnosed either by
water deprivation testing or by the presence of concur-
rent polyuria, hypernatremia, elevated serum osmolality,
low urine osmolality, and low urine specific gravity. The
prevalence of additional anterior pituitary hormone defi-
ciencies at each patient’s presentation and the incidence
of hormone deficiencies acquired later in the disease
course were also evaluated. The presence of a hormone
deficiency was confirmed by laboratory evidence of in-
sufficient hormone production.
Results
The cohort included 21 male patients and 14 female
patients whose median age at diagnosis of CDI was
4.8 years (range, less than 1 month to 16 years). In the
patients with CDI at their initial presentation, mean dur-
ation of symptoms prior to diagnosis was 6.3 months
(range, less than 1 week to 36 months). Characteristics
of the cohort and etiologies of CDI are reported in detail
in Table 1. Etiologies included CNS malformations in 17
patients (48.5 %), intracranial masses in 13 patients
(37.2 %), and Langerhans cell histiocytosis (LCH) in 3
patients (8.6 %). The underlying cause of CDI remains
unclear in 2 patients (5.7 %) but both had abnormal
MRI findings. Their cases are discussed in detail later in
the article. No patients had a family history of DI. Me-
dian duration of follow-up was 5 years (range, 2 months
to 16 years).
All patients underwent MRI of the brain. Thirty-three
patients had neuroimaging performed at NCCH, and re-
ports from referring hospitals were available for the
remaining 2 patients. All but one had abnormalities on
MRI of the brain including CNS malformations, intra-
cranial masses, pituitary gland or stalk abnormalities.
The one patient with a normal MRI of the brain was di-
agnosed with LCH (biopsy-proven) after presenting with
Table 1 Patient demographics and etiologies of central diabetes
insipidus
Demographics
Total Number of Patients, n 35
Female patients, n 14
Average Age of CDI Diagnosis, months 57.6 (0.73–192)
Time from Symptom Onset to CDI Diagnosis, months 6.4 (0.03–36)
Duration of Follow Up, months 60 (2.4–192)
Etiology n (%)
Central Nervous System Malformation 17 (48.5 %)
Septo-Optic Dysplasia 9 (25.7 %)
Holoprosencephaly 5 (14.2 %)
Pituitary Hypoplasia 2 (5.7 %)
Encephalocele 1 (2.9 %)
Intracranial Mass 13 (37.2 %)
Craniopharyngioma 6 (17.1 %)
Astrocytoma 3 (8.6 %)
Germinoma 3 (8.6 %)
Pituitary Adenoma 1 (2.9 %)
Langerhans Cell Histiocytosis 3 (8.6 %)
Unknown 2 (5.7 %)
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a posterior auricular mass. Of the 17 patients with CNS
malformations on MRI, 9 (25.7 %) had septo-optic
dysplasia (SOD), 5 (14.2 %) had holoprosencephaly, 2
(5.7 %) had isolated pituitary hypoplasia, and 1 (2.9 %)
had a large encephalocele. MRI revealed intracranial
masses in 13 patients (37.2 %), including craniopharyn-
gioma (6 patients, 17.1 %), astrocytoma (3 patients,
8.6 %), germ cell tumor (3 patients, 8.6 %), and pituitary
adenoma (1 patient, 2.9 %). Four patients had pituitary
stalk thickening. Of these patients, 2 were diagnosed
with LCH, 1 was diagnosed with a germ cell tumor, and
1 has not yet undergone biopsy to determine a definitive
diagnosis. One patient had absence of the posterior pitu-
itary bright spot alone, without other structural abnor-
malities on MRI.
Six of 35 patients required formal water deprivation
testing for diagnosis of CDI. The remaining patients
already fulfilled the diagnostic criteria. All patients who
required water deprivation test had abnormal findings
on MRI of the brain, and etiologies for CDI included
LCH, ectopic pituitary gland, pituitary hypoplasia, SOD,
astrocytoma, and pituitary adenoma. Two of 6 patients
had ADH deficiency alone at the time of diagnosis while
the remainder had concurrent hormone deficiencies at
presentation.
Twenty-one patients (60 %) had CDI at their initial
presentation and 10 patients (29 %) developed CDI as a
result of neurosurgical management of intracranial
masses (6 with craniopharyngioma, 2 with astrocytoma,
1 with germinoma, and 1 with adrenocorticoptropic hor-
mone (ACTH) secreting pituitary adenoma). Four pa-
tients (2 with SOD and 2 with ectopic posterior pituitary
glands) did not have CDI at presentation but developed
it during the follow-up period. One of the patients with
SOD was diagnosed with thyrotropin (TSH), ACTH, and
growth hormone (GH) deficiencies at birth but did not
develop symptoms of CDI until 2 months of age. The
second patient was diagnosed with SOD at 4 months of
age but did not develop CDI until 12 years of age. One
patient with an ectopic pituitary gland was diagnosed
with panhypopituitarism except CDI at 2 months of age
and developed CDI 1 year later. The other patient with
an ectopic pituitary gland presented with GH deficiency
and delayed puberty at 12 years of age and was diag-
nosed with CDI at 15 years of age.
GH deficiency was the most common concurrent hor-
mone deficiency at presentation in patients with CDI
and occurred in 12 patients (34 %). TSH, ACTH, and
gonadotropin deficiencies were present at the time of
diagnosis in 23 %, 23 %, and 6 % of patients, respectively.
TSH deficiency was subsequently diagnosed in an
additional 40 % of patients during follow-up. ACTH de-
ficiency and gonadotropin deficiencies were later diag-
nosed in 37 % and 14 % of patients, respectively (Figure 1).
Eighteen patients (51 %) were prepubertal in age so that
the presence of gonadotropin deficiencies could not be
assessed accurately. All 3 patients with LCH had CDI at
presentation, and 1 developed subsequent hormone de-
ficiencies as a result of disease progression and neuro-
surgery for diagnosis. Of the 5 patients with CDI as
a result of holoprosencephaly, only 1 developed an
additional hormone deficiency over time. The develop-
ment of additional anterior hormone deficiencies oc-
curred over time in 44 % of patients with SOD. Time
from diagnosis of SOD to onset of subsequent hormone
deficiencies ranged from months to years, with one
patient having a normal pituitary evaluation at 4 months
of age who did not develop subsequent hormone
deficiencies until 12 years of age (see Table 2).
There were 2 patients with CDI of unclear etiology.
The first patient has been followed at NCCH for 6 years.
He has undergone MRI of the brain on an annual basis
Fig. 1 Concurrent Hormone Deficiencies at Central Diabetes Insipidus Diagnosis and Acquired During Follow Up
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which has demonstrated a stable 4 mm focus of hypoen-
hancement within his right pituitary gland which may
represent a Rathke’s cleft cyst or adenoma; however, he
continues to follow-up with oncology given the possibil-
ity of LCH or germ cell tumor. He has had a total of two
osseous surveys (2 years apart) that have failed to dem-
onstrate evidence of LCH. He has undergone pituitary
hormone screening every 6 to 12 months without devel-
opment of subsequent hormone deficiencies. The other
patient with CDI of unknown etiology is 13 year old
female who presented for evaluation secondary amenor-
rhea, rapid weight gain, polydipsia and polyuria. She has
been followed in our clinic for nearly 1 year, and her
evaluation is significant for evidence of pituitary stalk
thickening with absence of the posterior pituitary bright
spot on MRI as well as TSH, GH, and gonadotropin
deficiencies. A skeletal survey was normal. Neurosurgery
has not yet agreed to obtain a biopsy for definitive
diagnosis.
CDI in 31 patients was successfully managed with
DDAVP. Chlorothiazide was used in 3 patients during in-
fancy. One patient was managed with oral free water in-
take alone per the family’s preference. One patient with an
astrocytoma had resolution of CDI after four years as a re-
sult of surgical intervention and chemotherapy.
Discussion
In our series of pediatric patients with CDI, nearly all
patients (97 %) had abnormalities on MRI of the brain,
with CNS malformations and intracranial masses being
the most common findings. Our findings are consistent
with a recent study by Werny at al [4] that reports a
higher prevalence of CNS malformations in patients
with CDI than previously reported, as well as fewer idio-
pathic cases. We identified tumors or LCH in nearly half
(46 %) of our patients with CDI, which is similar to the
rate of tumors and infiltrative processes (56 %) found by
Werny et al [4]. We did not identify any cases of famil-
ial/genetic, autoimmune, or idiopathic CDI, which is in-
consistent with other previous studies citing familial
causes in 7 % [4] and 6 % [5] and idiopathic etiology in
12 % [4] and 52 % [5]. These findings are likely a result
of our small sample size. Despite traumatic causes of
CDI being reported in 3 % of cases overall [5], we did
not identify any cases. This is likely due to the fact that
patients may have had either nonsurvivable brain injur-
ies or transient CDI, and we included only patients
followed in our outpatient clinic. Also congruent with
the Werny study, our patients with pituitary stalk thick-
ening were likely to be diagnosed with LCH or germ cell
tumor [4-6]. Given the high likelihood of identifying an
underlying etiology, it is of utmost importance to obtain
neuroimaging promptly in patients diagnosed with CDI.
In our cohort of patients with CDI, there was a high in-
cidence of concurrent anterior pituitary hormone defi-
ciencies. Hormone insufficiencies evolved over time in
many of our patients with CNS malformations, particu-
larly in those with SOD, or occurred abruptly as a result
of neurosurgical intervention in patients with intracra-
nial masses. Multiple pituitary hormone insufficiencies
were identified at the time of diagnosis in 89 % of pa-
tients with SOD. Forty-four percent of patients with
SOD developed additional hormone deficiencies any-
where from 2 months to 13 years after initial diagnosis
[7], highlighting the importance of regular screening.
This is in contrast to our patients with holoprosence-
phaly who were less likely to demonstrate evolution of
anterior pituitary hormone deficiencies over time. These
patients, who may have abnormal osmoreceptor function
(previously termed “essential hypernatremia”), as a result
of hypothalamic, rather than pituitary dysfunction [8, 9],
may warrant less diligent hormonal screening evalua-
tions over time compared to those with SOD; however,
larger studies are needed to identify appropriate time in-
tervals for repeat screening. The requirement for water
deprivation testing to achieve the diagnosis of CDI was
not associated with a specific underlying etiology or with
the presence or absence of concurrent hormone defi-
ciencies in our cohort.
CDI was managed successfully with DDAVP in the
majority of patients in our cohort; however, patients in
the neonatal period present a particular therapeutic
challenge [8]. In our experience, DDAVP titration was
problematic in such young patients and often resulted in
Table 2 Timing of development of pituitary hormone deficiencies in patients with cns malformations
Etiology Age at diagnosis of CNS abnormality Time from diagnosis of CNS abnormality to diagnosis of hormone deficiencies
Ectopic Pituitary 2 months ACTH, GH, TSH, at presentationADH, 1 year
Holoprosencephaly 3 months ADH, at presentationTSH, 2 years
Pituitary Hypoplasia 13 years GH, at presentationTSH, 9 monthsADH, 2 yearsFSH, LH, 3 years
Septo-Optic Dysplasia 2 days ACTH, GH, TSH, at presentationADH, 2 months
Septo-Optic Dysplasia 4 months GH,12 yearsACTH, ADH, TSH, 13 years
Septo-Optic Dysplasia 8 months ADH, GH, at presentationTSH, 1 year
Septo-Optic Dysplasia 22 months ADH, GH, at presentationACTH, 2 years
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wide fluctuations in sodium levels, including severe hypo-
natremia that occasionally resulted in seizures. In agree-
ment with previous reports, we have been able to maintain
acceptable sodium concentrations using chlorothiazide and
low solute formula in infants up to 6 months of age, after
which DDAVP doses may be titrated more easily [10, 11].
There are some limitations to our study that should be
considered. First, the retrospective nature of our study
results in inter-patient variability in the diagnosis of pi-
tuitary hormone deficiencies (random laboratory values
versus provocative testing) and evaluation of hormone
deficiencies over time. Furthermore, diagnostic labora-
tory data was limited in patients that had begun hor-
mone replacement therapy prior to referral to our clinic.
It is also likely that the incidence of gonadotropin defi-
ciency is underreported given that many of our patients
are too young to manifest symptoms of delayed puberty.
Additionally, variability in MRI interpretation may result
in under or over reporting of pituitary abnormalities.
Finally, our population may not be representative of all
children with CDI because we included only patients
followed in the outpatient setting, excluding those with
nonsurvivable CNS insults or transient CDI.
Conclusions
Most children with CDI have abnormal findings on MRI
of the brain, with intracranial masses and CNS malforma-
tions being most common. Therefore, the diagnosis of
idiopathic CDI should be made with extreme caution in
children, and only after extensive evaluation, including
MRI of the brain, has been obtained. GH deficiency was
the most common concurrent hormone deficiency at
presentation in patients with CDI. TSH and ACTH defi-
ciencies were more commonly diagnosed during follow-
up evaluation; however, the development of additional
hormone deficiencies in patients who did not undergo
surgical intervention remains unpredictable, especially in
those with SOD. Continued screening for endocrine dys-
function is warranted though further studies are needed
to determine the most appropriate screening interval.
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